Literature DB >> 17503430

Manipulating the chemokine-chemokine receptor network to treat cancer.

Pier A Ruffini1, Paolo Morandi, Neslihan Cabioglu, Kadri Altundag, Massimo Cristofanilli.   

Abstract

Chemokines are chemoattractant cytokines that regulate the trafficking and activation of leukocytes and other cell types under a variety of inflammatory and noninflammatory conditions. Over the past few years, studies have increasingly shown that chemokines play an important role in several aspects of tumor progression. Tumor cells express functional chemokine receptors, which can sustain proliferation, angiogenesis, and survival and promote organ-specific localization of distant metastases. Chemokine expression in human malignancies is associated with a leukocyte infiltration favoring the establishment of immune escape mechanisms. A literature review of relevant publications on preclinical testing of cancer therapies based on interference with the cancer chemokine network was performed. The feasibility, potential advantages, and limitations of the clinical translation of the results of such studies in treatment of different tumor types and settings are discussed. The chemokine network is a key player in the establishment of metastases. In the preclinical setting, blocking agents and antibodies directed against CXCR4 prevent metastasis of different cancers. In mouse models, overexpression of selected chemokines causes tumor infiltration by distinct leukocyte subsets, resulting in tumor regression and tumor-specific immunity generation. Researchers have also successfully used chemokines as carriers and/or adjuvants for cancer vaccines. The cancer chemokine network is a multifaceted therapeutic target. Copyright 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503430     DOI: 10.1002/cncr.22706

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.

Authors:  Michelle L Varney; Seema Singh; Aihua Li; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

Review 2.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

3.  Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.

Authors:  Shaheenah Dawood; Yun Gong; Kristine Broglio; Thomas A Buchholz; Wendy Woodward; Anthony Lucci; Vicente Valero; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Massimo Cristofanilli
Journal:  Breast J       Date:  2010-07-06       Impact factor: 2.431

4.  Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.

Authors:  N Cabioglu; A A Sahin; P Morandi; F Meric-Bernstam; R Islam; H Y Lin; C D Bucana; A M Gonzalez-Angulo; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 5.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

6.  Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma.

Authors:  Jun Pu Wang; Wan Ming Hu; Kuan Song Wang; Bai Hua Luo; Chang Wu; Zhi Hong Chen; Geng Qiu Luo; Yu Wu Liu; Qin Lai Liu; Jun Yu; Jing He Li; Ji Fang Wen
Journal:  Exp Ther Med       Date:  2012-05-07       Impact factor: 2.447

7.  CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation.

Authors:  Alex J Carlisle; Christopher A Lyttle; Rosalind Y Carlisle; John M Maris
Journal:  Mol Cancer       Date:  2009-12-22       Impact factor: 27.401

8.  Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.

Authors:  Ke Zheng; Hong-Yuan Li; Xin-Liang Su; Xiao-Yi Wang; Tian Tian; Fan Li; Guo-Sheng Ren
Journal:  J Exp Clin Cancer Res       Date:  2010-04-11

9.  Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.

Authors:  M Pfeiffer; T N Hartmann; M Leick; J Catusse; A Schmitt-Graeff; M Burger
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

10.  Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients.

Authors:  Frank M Speetjens; Gerrit Jan Liefers; Cornelis J Korbee; Wilma E Mesker; Cornelis J H van de Velde; Ronald L van Vlierberghe; Hans Morreau; Rob A Tollenaar; Peter J K Kuppen
Journal:  Cancer Microenviron       Date:  2008-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.